Alpha-1 antitrypsin (AAT) deficiency is a condition in which the body does not make enough of AAT, a protein that protects the lungs and liver from damage. The condition can lead to chronic obstructive pulmonary disease (COPD) and liver disease (cirrhosis).
AAT deficiency; Alpha-1 protease deficiency; COPD - alpha-1 antitrypsin deficiency; Cirrhosis - alpha-1 antitrypsin deficiency
AAT is a type of protein called a protease inhibitor. AAT is made in the liver and it works to protect the lungs and liver.
AAT deficiency means there is not enough of this protein in the body. It is caused by a genetic defect. The condition is most common among Europeans and North Americans of European descent.
Adults with severe AAT deficiency will develop emphysema, sometimes before 40 years of age. Smoking can increase the risk for emphysema and make it occur earlier.
Symptoms may include any of the following:
Treatment for AAT deficiency involves replacing the missing AAT protein. The protein is given through a vein each week or every 4 weeks. This is only slightly effective at preventing more lung damage in people without end-stage disease. This procedure is called augmentation therapy.
If you smoke, you need to quit.
Other treatments are also used for COPD and cirrhosis.
Lung transplant can be used for severe lung disease, and liver transplant can be used for severe cirrhosis.
Robert Stockley practices in Birmingham, United Kingdom. Stockley is rated as an Elite expert by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). He is also highly rated in 7 other conditions, according to our data. His top areas of expertise are Subcutaneous Emphysema, Alpha-1 Antitrypsin Deficiency (AATD), Emphysema, and Chronic Obstructive Pulmonary Disease (COPD).
Robert Sandhaus is a Pulmonary Medicine expert in Denver, Colorado. Sandhaus has been practicing medicine for over 47 years and is rated as an Elite expert by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). He is also highly rated in 4 other conditions, according to our data. His top areas of expertise are Alpha-1 Antitrypsin Deficiency (AATD), Emphysema, Subcutaneous Emphysema, and Chronic Obstructive Pulmonary Disease (COPD). Sandhaus is currently accepting new patients.
Mark Brantly is a Pulmonary Medicine expert in Gainesville, Florida. Brantly has been practicing medicine for over 44 years and is rated as an Elite expert by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). He is also highly rated in 5 other conditions, according to our data. His top areas of expertise are Emphysema, Alpha-1 Antitrypsin Deficiency (AATD), Subcutaneous Emphysema, Lymphangioleiomyomatosis, and Lung Transplant. Brantly is currently accepting new patients.
Some people with this deficiency will not develop liver or lung disease. If you quit smoking, you can slow the progression of the lung disease.
COPD and cirrhosis can be life threatening.
Complications of AAT deficiency include:
Contact your provider if you develop symptoms of AAT deficiency.
Summary: The Alpha-1 Research Registry is a confidential database made up of individuals diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1) and individuals identified as Alpha-1 carriers. The Registry was established to facilitate research initiatives and promote the development of improved treatments and a cure for Alpha-1.
Summary: This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD). The study will be conducted in 3 separate cohorts. A total of up to 16 participants may be enrolled in Cohort 1 and 2. A total number of 30 subjects will be enrolled in cohort 3. The 3 cohorts a...
Published Date: July 31, 2022
Published By: Denis Hadjiliadis, MD, MHS, Paul F. Harron, Jr. Professor of Medicine, Pulmonary, Allergy, and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Han MK, Lazarus SC. COPD: diagnosis and management. In: Broaddus VC, Ernst JD, King TE, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 7th ed. Philadelphia, PA: Elsevier; 2022:chap 64.
Hatipoglu U, Stoller JK. a1 -antitrypsin deficiency. Clin Chest Med. 2016;37(3):487-504. PMID: 27514595 pubmed.ncbi.nlm.nih.gov/27514595/.
Winnie GB, Boas SR. a1 -antitrypsin deficiency and emphysema. In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier; 2020:chap 421.